Abstract:Background Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addressed. The aim of this study was to assess the correlation between risk of CVEs and AIs in patients with breast cancer. Methods Included studies were obtained from the databases of Embase, Pubmed, Cochrane Library, Clinical Trials.gov, and reference lists. The main outcome measures were overall incidence, odds ratios (ORs), and 95% confidence intervals (CIs). Furthermore, the association and the risk differences among different tumor types, AIs,ages,or treatment regimens were conducted. Fixed-effect or random-effect models were applied in the statistical analyses according to the heterogeneity. Our analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results Seventeen studies, which included 44,411 subjects, were included in our analyses. The overall incidence of CVEs in AIs group was 13.02% (95% CI: 8.15–20.17%) and almost all of the high-grade CVEs occurred in patients treated with AIs. The pooled ORs of CVEs was 0.9940 (95% CI: 0.8545–1.1562). Under sub-group analysis, the incidence of CVEs related to exemestane was higher than that of controls (OR = 1.1564, 95% CI: 1.0656–1.2549), but no statistical differences in risk of CVEs were found in other sub-group analysis. No evidence of publication bias was found for incidence of CVEs in our meta-analysis by a funnel plot. Conclusions These results suggest that patients with breast cancer treated with AIs do not have a significant risk of developing CVEs in comparison with the controls, and exemestane might not be considered as the alternative AI to the breast cancer patients from the perspective of CVEs. Further studies are recommended to investigate this association and the risk differences among different tumor types, AIs or treatment regimens.

α-Zearalanol, a phytoestrogen for cardiovascular therapy

Phytoestrogen α-zearalanol inhibits atherogenesis and improves lipid profile in ovariectomized cholesterol-fed rabbits

RETRACTED: Phytoestrogen Α-Zearalanol Inhibits Homocysteine-Induced Endothelin-1 Expression and Oxidative Stress in Human Umbilical Vein Endothelial Cells

Phytoestrogen Α-Zearalanol Antagonizes Oxidized LDL-Induced Inhibition of Nitric Oxide Production and Stimulation of Endothelin-1 Release in Human Umbilical Vein Endothelial Cells

Phytoestrogen Α-Zearalanol Antagonizes Homocysteine-Induced Imbalance of Nitric Oxide/endothelin-1 and Apoptosis in Human Umbilical Vein Endothelial Cells

The Nfluence of Conjugested Estrogen Therapy on Cardiovascular Function in Postmenopausal Women

Aromatase Inhibitors and Risk of Cardiovascular Events in Breast Cancer Patients: a Systematic Review and Meta-Analysis

Comparison of cardiac contractile and intracellular Ca 2+ response between estrogen and phytoestrogen α-zearalanol in ventricular myocytes

Alpha-Zearalanol Attenuates Oxldl-Induced ET-1 Gene Expression, ET-1 Secretion and Redox-Sensitive Intracellular Signaling Activation in Human Umbilical Vein Endothelial Cells.

Activation of estrogen receptor α (ERα) is required for Alisol B23-acetate to prevent post-menopausal atherosclerosis and reduced lipid accumulation

The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy

Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

17SS-Estradiol Antagonizes the Down-Regulation of ERα/NOS-3 Signaling in Vascular Endothelial Dysfunction of Female Diabetic Rats.

Selective Estrogen Receptor Modulator Effects on Serum Lipoproteins and Vascular Function in Postmenopausal Women and in Hypercholesterolemic Men

17β-Estradiol inhibits oleic acid-induced rat VSMC Proliferation and migration by restoring PGC-1α expression

Nonnuclear Estrogen Receptor Activation Improves Hepatic Steatosis in Female Mice.

Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats

The Chondroprotective Effects of Dehydroepiandrosterone Probably Exerted by Its Conversion to Estradiol

Effects of Transdermal 17β-Estradiol + Norethisterone Acetate on Cardiovascular Disease Risk Factors in Postmenopausal Women: A Meta-analysis of Data From Randomized, Controlled Trials

Alpha-Lipoic Acid Protects Human Aortic Endothelial Cells Against H2O2-Induced Injury and Inhibits Atherosclerosis in Ovariectomized Low Density Lipoprotein Receptor Knock-Out Mice

Comparison of Phytoestrogens Therapy with Hormone Replacement Therapy